The Therapeutic Effect of Inhaled Iloprost in Newborn Infants with Severe Persistent Pulmonary Hypertension Refractory to Inhaled Nitric Oxide.
- Author:
Yoon Ki HAN
1
;
Soon Min LEE
;
Ho Seon EUN
;
Jeong Eun KIM
;
Ran NAMGUNG
;
Min Soo PARK
;
Kook In PARK
;
Chul LEE
Author Information
1. Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul, Korea. ranng@yuhs.ac
- Publication Type:Case Report
- Keywords:
Iloprost;
Persistent pulmonary hypertension of the newborn;
Nitric oxide
- MeSH:
Adult;
Critical Care;
Epoprostenol;
Humans;
Hypertension, Pulmonary;
Iloprost;
Infant, Newborn;
Nitric Oxide
- From:Korean Journal of Perinatology
2011;22(1):57-63
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Inhaled iloprost, a stable carbacyline derivative of prostacyclin, has been used recently for the treatment of adults with pulmonary hypertension but only few reports are available about its use in neonatal critical care. We report therapeutic trial of inhaled iloprost in newborn infants with persistent pulmonary hypertension of the newborn (PPHN) who did not respond to inhaled nitric oxide (iNO). Inhaled iloprost (Ventavis(R), Bayer Shering Pharma, Germany) was effective in neonates with severe PPHN who showed inadequate response to iNO. We suggest that inhaled iloprost could be considered as an additional therapeutic option in PPHN refractory to iNO.
